Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Trevi Therapeutics (NASDAQ:TRVI) and maintained an $8 price target.
August 11, 2023 | 9:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Trevi Therapeutics and maintained an $8 price target.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of an $8 price target could potentially boost investor confidence in Trevi Therapeutics, leading to a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100